Business
Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update
Webcast to be held Wednesday, December 3, at 8:00am ET CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, will host a webcast to present results from its Phase 2 clinical trial of silevertinib and provide a program update on Wednesday, December 3, 2025, at 8:00am ET. Webcast information The webcast can be accessed
About this update from Black Diamond Therapeutics, Inc.
[{"type":"image","alt":"Black Diamond Therapeutics, Inc","displaySize":"","headline":null,"caption":"Black Diamond Therapeutics, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":89,"url":"https://media.zenfs.com/en/globenewswire.com/497f244e89de775874fac406d50e11cb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vwkphi42thFYY0QCBIsk8Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/497f244e89de775874fac406d50e11cb","width":300,"height":89}},"lazy":false},{"type":"text","content":"Webcast to be held Wednesday, December 3, at 8:00am ET","length":54,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, will host a webcast to present results from its Phase 2 clinical trial of silevertinib and provide a program update on Wednesday, December 3, 2025, at 8:00am ET.","length":396,"tagName":"p"},{"type":"text","content":"Webcast information","length":19,"tagName":"p"},{"type":"text","content":"The webcast can be accessed under “Events and Presentations” on the Investors section of the Black Diamond website at www.blackdiamondtherapeutics.com. A replay of the webcast will be available following the completion of the event.","length":237,"tagName":"p"},{"type":"text","content":"About Black Diamond Therapeutics","length":32,"tagName":"p"},{"type":"text","content":"Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 non-small cell lung cancer (NSCLC) trial of silevertinib, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. For more information, please visit www.blackdiamondtherapeutics.com.","length":703,"tagName":"p"},{"type":"text","content":"From time to time, we may use our website or...